PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsNeuroscienceSchizophrenia
  • Cadent announces FDA Clearance of IND of CAD-9303 for Schizophrenia

    • March 11, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • FDA Approves Perseris (risperidone) for Schizophrenia treatment in Adults

    • August 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • FDA Approves new Initiation drug, ARISTADA INITIO, for Schizophrenia

    • July 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Rxulti (brexpiprazole) for Schizophrenia gets positive CHMP opinion by EMA

    • June 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Recent study identified Brain cells underlying Schizophrenia

    • May 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Alkermes to Present Clinical Data related to Schizophrenia and Depression at American Psychiatric Association Annual Meeting

    • May 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Schizophrenia drug ALKS 3831 completes Patient enrollment in a pivotal study

    • April 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
Newsletter
Recent Posts
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare
  • Social Media Analytics in Healthcare
  • Importance of KOL Analytics in the Healthcare domain

Contact Us

   enquiry@pharmascroll.com
   +919311760222

   Indian Address: PhamaScroll Research and Consulting Private Limited, 91 Springboard, 4th floor, F948+W7, Laxmi Cyber City, Whitefields, Hyderabad, Telangana 500081

    US address: 12 Self Ct, Wallingford CT 06492

Recent Tweets

  • The FDA has approved Menarini's Orserdu (elacestrant) as a second-line treatment for advanced breast cancer with ES… https://t.co/vUiNkpOSQs2 hours ago
  • The European Commission approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for patients wit… https://t.co/huyODDdHeA4 days ago

Recent Posts

  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare

News Letter

© 2023 Copyright. All rights reserved

Catalyzed by

SPEAK TO AN EXPERT